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1650Objectives:Dysregulation of extracellular matrix (ECM) following myocardial infarction is a key contributor to
myocardial fibrosis, chamber dilation, and progression to heart failure. Basic fibroblast growth factor is a potent
inhibitor of fibrosis. We propose a novel surgical procedure leveraging a commercially available ECM
biomaterial for the treatment of ischemic heart failure.
Methods: Epicardial infarct repair using CorMatrix-ECM biomaterial patch (CorMatrix Cardiovascular Inc,
Roswell, Ga) was compared with sham in a rat myocardial infarction model. Key indices of ischemic remodel-
ing, including inflammation, fibrosis, and myocardial performance were evaluated 16 weeks post-treatment.
Results: Histology and immunohistochemistry demonstrated comprehensive integration of CorMatrix-ECM
biomaterial patch without evidence of immune reaction and an increase in basic fibroblast growth factor
expression in treated animals. Functional analysis by serial echocardiography of normal (n ¼ 13), sham
(n ¼ 15), nonenhanced CorMatrix-ECM patch (n ¼ 18), and basic fibroblast growth factor–enhanced
CorMatrix-ECM patch (n¼ 10) animals revealed an improvement in ejection fraction in basic fibroblast growth
factor–enhanced CorMatrix-ECM patch animals compared with shams (55.3%  8.0% vs 35.1%  7.6%;
P<.001). Prevention of left ventricle remodeling was also confirmed by pressure volume loop analysis, which
demonstrated reduced left ventricular end diastolic volumes in basic fibroblast growth factor–enhanced
CorMatrix-ECM patch animals (n ¼ 5) compared with shams (n ¼ 6) (208.0  59.3 mL vs 363. 1  108.7
mL; P<.01) and improved left ventricle contractility in nonenhanced CorMatrix-ECM patch (n ¼ 7) and basic
fibroblast growth factor-enhanced CorMatrix-ECM patch animals compared with shams (0.709  0.306 and
0.609  0.160 vs 0.437  0.218; P<.05).
Conclusions: Epicardial infarct repair with basic growth factor–enhanced CorMatrix-ECM biomaterial patch
attenuates myocardial remodeling and improves cardiac performance after subacute myocardial infarction in
a rat coronary ligation model. These observations establish proof-of-concept for this novel surgical approach.
(J Thorac Cardiovasc Surg 2014;147:1650-9)Survival rates following acute myocardial infarction (MI)
are improving and the incidence of ischemic heart failure
is reaching epidemic proportions.1 Interstitial fibrosis and
progressive ventricular dilation, 2 hallmarks of ischemic
heart failure, are the result of structural remodeling in
both the infarcted and remote myocardium. Restoring
myocardial perfusion by revascularization after MI is bene-
ficial but does not prevent maladaptive post-MI remodeling.
Adjunctive therapies at the time of surgical revasculariza-
tion that target the injured region may prevent or limite Campbell Cardiovascular Translational Research Program, Division of Car-
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The Journal of Thoracic and Cardiovascular Surstructural cardiac remodeling and in so doing improve
outcomes for patients with ischemic injury.
In our study, we examined the utility of basic fibroblast
growth factor (bFGF)–enhanced CorMatrix-ECM biomate-
rial patches (CorMatrix Cardiovascular Inc, Roswell, Ga) as
a novel surgical epicardial patch repair after subacute MI in
rodents. To establish proof-of-concept, we determined
its biocompatibility in host myocardium, expression of ma-
tricellular proteins after patch implantation, and procedural
effectiveness in limiting progressive adverse structural
remodeling after ischemic injury.METHODS
Experiment Animals
The experiment protocol was approved by the Institutional Animal Care
Committee. All procedures performed were in accordance with the Guide
for the Care and Use of Experimental Animals from the Canadian Council
on Animal Care2 and the Guide for the Care and Use of Laboratory Ani-
mals.3 Male rats (Fischer CDF strain) weighing between 170 and 200 g
were obtained fromCharles River Canada Inc (Montreal, Quebec, Canada).gery c May 2014
Abbreviations and Acronyms
bFGF ¼ basic fibroblast growth factor
ECM ¼ extracellular matrix
MI ¼ myocardial infarction
PBS ¼ phosphate buffered saline
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Animals were anesthetized with isoflurane (4%), intubated, and main-
tained on continuous ventilation with medical-grade oxygen supplemented
with isoflurane (1%-2%) for the duration of the surgical procedure. The
heart was exposed via a left anterolateral thoracotomy. The pericardium
was incised and the left anterior descending artery was identified and prox-
imally ligated using interrupted 7-0 polypropylene sutures. The incision
was reapproximated and animals were recovered. Analgesia included bu-
prenorphine (Hospira Healthcare Corp, Lake Forest, Ill) 0.03 mg/kg preop-
eratively, 4 to 8 hours postoperatively, and repeated as necessary every
8 hours for the first 24 hours postoperatively; 2% lidocaine on the endotra-
cheal tube tip at the time of intubation; and 2% lidocaine within the skin
incision before closure. Animals were administered 150,000 IU/kg Duplo-
cillin LA antibiotic (Intervet Canada Ltd, Kirkland, Quebec, Canada) and
10 cc/kg normal saline (0.9% sodium chloride) preoperatively.
CorMatrix-ECM Biomaterial
A commercially available extracellular matrix (ECM) biomaterial pro-
cured from porcine small intestine submucosa was obtained. Nonenhanced
CorMatrix-ECMpatch was prepared for surgical implantation by soaking it
in phosphate buffered saline (PBS) (Lonza Group, Basel, Switzerland) for a
minimum of 2 hours at 37C. bFGF enhancement was achieved by soaking
the CorMatrix-ECMmaterial in 40 mL of 25 mg/mL bFGF (Invitrogen Cor-
poration, Carlsbad, Calif) in PBS for a minimum of 2 hours at 37C and
then rinsing the material with PBS before implantation. Enhancement of
the CorMatrix-ECM material with bFGF was evaluated before implanta-
tion by Western blot as previously described.4
Epicardial Infarct Repair Procedure
Successfully infarcted animals were randomly assigned to 1 of 3 groups:
nonenhanced epicardial infarct repair, bFGF-enhanced epicardial infarct
repair, or sham procedure. Three weeks post-MI, rats were anesthetized
andmaintained as described above. The heart was exposed via a left antero-
lateral thoracotomy 1 intercostal space caudal to the previous incision. The
infarcted region was identified visually. Animals randomized to 1 of the
treatment groups received either nonenhanced or bFGF-enhanced
CorMatrix-ECM patch sewn onto the epicardial surface of the infarct using
a continuous 7-0 polypropylene suture. Animals randomized to the sham
group underwent a similar suture technique performed without securing
a CorMatrix-ECM patch. The incision was reapproximated and the animals
were recovered. Analgesia, antibiotic prophylaxis, and preoperative fluids
were administered as described above.
Histology and Immunohistochemistry
Animals were euthanized and hearts explanted 16 weeks after treat-
ment. The left ventricle was isolated and long axis sections were fixed in
10% neutral buffered formalin and embedded in paraffin. Samples were
stained with hematoxylin and eosin or Masson’s trichrome to evaluate inte-
gration of the CorMatrix-ECM patch material. Autofluorescent back-
ground signals was reduced using 50 mM ammonia in 70% ethanol for
180 minutes, followed by 5 minutes in 0.1% Sudan black B in 70%
ethanol.5 Antigen retrieval was performed on all samples before immuno-
fluorescent staining by incubating slides in 10 mM citric acid in 0.05%
Tween detergent at a pH of 6.0 for 60 minutes at 95C to 100C. ProteinaseThe Journal of Thoracic and CarK antigen retrieval protocol was used on collagen type I antibodies, in addi-
tion to citric acid antigen retrieval. TE buffer (50 mM Tris base, 1 mM thy-
lenediaminetetraacetic acid, 0.5% Triton X-100, pH 8.0) with proteinase K
(20 mg/mL) was incubated for 20 minutes at 37C in a humidified chamber
and washed off with TE buffer in 5% goat serum. Samples were blocked
with 5% goat serum 0.1% Triton X-100 in PBS for 1 hour, then stained us-
ing primary troponin (Developmental Studies Hybridoma Bank, Iowa City,
Iowa), collagen type I (Abcam, Cambridge, Mass), alpha smooth muscle
actin (Sigma-Aldrich, St Louis, Mo), and basic-fibroblast growth factor an-
tibodies (Santa Cruz Biotechnology, Inc, Dallas, Tex). Nuclei were stained
with 4’6-diamino2-phenylindol. Stained specimens were examined using a
Zeiss Axiovert 40X light microscope (Carl Zeiss Canada, Ontario, Canada)
and a Zeiss LSM-5 Laser ConfocalMicroscope (Carl Zeiss GmBH,Heidel-
berg, Germany).
Echocardiography
Echocardiographic evaluation was performed 2 weeks post-infarct (as a
baseline before treatment), and between 16 and 19 weeks after treatment.
All echocardiograms were performed under isoflurane inhalational anes-
thesia in the dorsal decubitus position, and recorded using an Esaote
MyLab30 Gold Cardiovascular Ultrasound system (Canadian Veterinary
Imaging, Georgetown, Ontario, Canada). Animals with an ejection fraction
>60% measured by echocardiography were not randomized.
Pressure Volume Loop Analysis
Hemodynamic parameters were further assessed using a pressure vol-
ume loop system 16 to 19 weeks after treatment. A 2F conductance catheter
(SPR-838 or SPR849, Millar Instruments, Houston, Tex) was inserted into
the left ventricle via the right carotid artery. The appropriate catheter length
was chosen based on the long axis measurement of the left ventricle deter-
mined via echocardiography. Left ventricular pressure and volume data
was collected and analyzed as previously described6 using ADInstruments
software (Colorado Springs, Colo).
Ex Vivo Passive Left Ventricle Pressure-Volume
Assessment
After diastolic arrest, a latex balloon coupled to a pressure catheter
was inserted into the left ventricle and passive pressure distention mea-
sures were performed as previously described.7 Left ventricle volume
was determined by the volume of saline injected into the balloon to
achieve 30 mm Hg.
Statistical Analysis
All data are expressed as mean  standard deviation. Prism 5.0d
(GraphPad Software Inc, La Jolla, Calif) statistical software was used for
all statistical analysis. Data was analyzed by 1-way analysis of variance,
repeated measures analysis of variance, and unpaired t test where appro-
priate.Multiple comparisons were performed using the Bonferroni method.RESULTS
A total of 56 rats were evaluated in this study (normal,
n ¼ 13; nonenhanced ECM, n ¼ 18; bFGF-enhanced
ECM, n ¼ 10; and sham, n ¼ 15). No animals were lost
during the period of follow-up. All animals had serial
echocardiography assessments. A random sample of 5 per
group received histologic analysis. A random sample
of animals received invasive hemodynamic assessments
and passive pressure-volume analysis without histologic
analysis (normal, n ¼ 8; nonenhanced ECM, n ¼ 7;
bFGF-enhanced ECM, n ¼ 5; and sham, n ¼ 6).diovascular Surgery c Volume 147, Number 5 1651
FIGURE 1. A, Left ventricles (LVs) transected longitudinally through the anterior and posterior walls to reveal the infarcted myocardium within the ante-
rior wall (indicated by the arrowheads). B, Passive pressure distension was performed in explanted LVs from normal, sham, nonenhanced CorMatrix-ECM
patch (CorMatrix Cardiovascular Inc, Roswell, Ga), and basic fibroblast growth factor (bFGF)–enhanced CorMatrix-ECM patch animals (n¼ 5 per group).
The LV volume at 30 mm Hg was recorded and compared between groups as an index of chamber size. C, Passive pressure-volume curves from normal,
nonenhanced, and sham animals are shown and confirm that chamber compliance was similar between groups. *P<.05. ECM, Extracellular matrix.
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extensive regional scarring in sham animals compared
with non-enhanced and bFGF-enhanced CorMatrix–ECM-
treated animals (Figure 1, A). The infarct region was thinner
in sham animals compared with both nonenhanced and
bFGF-enhanced CorMatrix-ECM patch animals, with the
appearance of healthy myocardium toward the endocardial
surface under the patch in bFGF-enhanced CorMatrix-ECM
patch animals. By gross examination the left vetricle
appeared dilated in sham animals compared with normal,
nonenhanced and bFGF-enhanced CorMatrix-ECM patch
animals. This observation was confirmed by ex vivo passive1652 The Journal of Thoracic and Cardiovascular Surpressure measures of left ventricle volumes, which demon-
strated an increase in left ventricle volumes for sham
animals compared with normal, nonenhanced, and bFGF-
enhanced CorMatrix–ECM-treated animals (360.0  54.8
mL vs 204.0  83.0 mL, 260.0  95.9 mL, and 240.0 
49.0 mL; P ¼ .02) (Figure 1, B). Histologic examination
of explanted LV myocardium demonstrated integration of
the CorMatrix-ECM material with host myocardium
(Figure 2, A). No evidence of an immune reaction to the ma-
terial was observed 16 weeks post-treatment. Integration
was also assessed by immunohistochemistry (Figure 2, B),
which showed the ECM transition from the host to thegery c May 2014
FIGURE 2. Myocardial tissue from a nonenhanced CorMatrix-ECM patch (CorMatrix Cardiovascular Inc, Roswell, Ga) animal. A, Histology. B, Immu-
nohistochemistry. Arrowheads outline the myocardium-patch interface, green color indicates troponin, orange color indicates collagen, and blue indicates
nucleus. *CorMatrix-ECM patch material.
Mewhort et al Evolving Technology/Basic Science
E
T
/B
Simplanted patch was free of scarring or inflammatory reac-
tivity. Healthy troponin expressing myocytes were observed
within the infarct area below the CorMatrix-ECM patch
suggesting muscle preservation.The Journal of Thoracic and CarImmunohistochemistry for Type-I collagen highlighted
the architecture of ECM in healthy myocardium (Figure 3,
A) compared with infarcted myocardium in sham
animals (Figure 3, B), non-enhanced CorMatrix-ECMdiovascular Surgery c Volume 147, Number 5 1653
FIGURE 3. Immunohistochemistry. A, Normal myocardium. B, Infarcted myocardium from a sham. C, Nonenhanced CorMatrix-ECM patch (CorMatrix
Cardiovascular Inc, Roswell, Ga). D, Basic fibroblast growth factor (bFGF)–enhanced CorMatrix-ECM patch animal stained with anti-collagen (orange)
and 406-diamino2-phenylindol (blue). E, In vivo CorMatrix-ECM patch stained with anti-collagen (orange). F, In vivo CorMatrix-ECM patch stained with
anti-alpha-smooth muscle actin (green) and 406-diamino2-phenylindol (blue). SIS ECM, Small intestine submucosa extracellular matrix.
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animals (Figure 3, D). Collagen matrix within the infarct
area of sham animals appeared denser than CorMatrix–
ECM-treated animals, suggesting ECM dysregulation. The
cardiac ECM architecture appeared more preserved in
both the nonenhanced and bFGF-enhanced CorMatrix–
ECM-treated animals, also supporting improving ECM
homeostasis. In addition, the acellular implant was1654 The Journal of Thoracic and Cardiovascular Surrepopulated with host cells suggesting de novo tissue forma-
tion in the infarct region. Immunohistochemistry of the
CorMatrix-ECM patch in vivo demonstrated incorporation
of host cells as represented by frequent nuclei (blue) present
throughout the CorMatrix-ECM implant material (Figure 3,
E). The cells within the implanted material stained positive
for a-smooth muscle actin, possibly reflecting vascular
smoothmuscle cells, (myo) fibroblasts or others (Figure 3,F).gery c May 2014
FIGURE 4. CorMatrix-ECM patch (CorMatrix Cardiovascular Inc, Roswell, Ga) animal stained with anti-basic fibroblast growth factor (bFGF) (red)
and 406-diamino2-phenylindol (blue). A, In vivo nonenhanced. B, bFGF-enhanced. C, CorMatrix-ECM and infarcted myocardium from a sham.
D, Nonenhanced. E, bFGF-enhanced. F, Western blot for bFGF performed on the bFGF-enhanced CorMatrix-ECM patch before implantation.
SIS ECM, Small intestine submucosa extracellular matrix.
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ter epicardial implantation demonstrated increased bFGF
expressing cells within the bFGF-enhanced CorMatrix-
ECM compared with nonenhanced CorMatrix-ECM
(Figure 4, A and B). Evaluation of bFGF concentration
following the in vitro enhancement procedure demonstrated
a marked uptake of bFGF within the CorMatrix-ECM
biomaterial before epicardial implantation (Figure 4, F).
Notably, after 16 weeks in vivo, bFGF expression withinThe Journal of Thoracic and Carthe CorMatrix-ECM implant localized to cell membranes
suggesting that late bFGF expression was the result of
bFGF-expressing host cells that infiltrated the CorMatrix-
ECM material rather than nonspecific residual bFGF from
the earlier enhancement procedure. bFGF was also up-
regulated within the infarcted myocardium of nonenhanced
CorMatrix-ECM and to an even greater extent in bFGF-
enhanced CorMatrix–ECM-treated animals when compared
with shams (Figure 4, C-E). These data support thediovascular Surgery c Volume 147, Number 5 1655
FIGURE 5. Hemodynamic parameters. A, Ejection fraction measured 16
weeks post-treatment by echocardiography in normal (n ¼ 13), sham
(n ¼ 15), nonenhanced CorMatrix-ECM patch (CorMatrix Cardiovascular
Inc, Roswell, Ga) (n ¼ 18), and basic fibroblast growth factor (bFGF)–
enhanced CorMatrix-ECM patch (n ¼ 10) animals. B, Pressure-volume
(PV) loop analysis in normal (n ¼ 8), sham (n ¼ 6), nonenhanced
CorMatrix-ECM patch (n ¼ 7), and bFGF-enhanced CorMatrix-ECM
patch (n ¼ 5) animals. C, Changes in ejection fraction measured by echo-
cardiography over the time course of the experiment in normal (n ¼ 13),
sham (n ¼ 15), and CorMatrix-ECM patch (n ¼ 28; patch group includes
non-enhanced and bFGF-enhanced CorMatrix-ECM patch) animals. D,
Left ventricular end diastolic volume (LVEDV) measured by PV loop 16
weeks post-treatment. E, Contractility was reflected by the end systolic
=
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implantation.
Echocardiography demonstrated an improvement in
ejection fraction over 16 weeks in bFGF-enhanced CorMa-
trix–ECM-treated animals compared with shams (55.3%
8.0% vs 35.1%  7.6%; P< .001) (Figure 5, A). The
improvement in ejection fraction was also confirmed by
pressure volume loop analysis (58.7%  11.2% vs
33.8%  7.5%; P < .001) (Figure 5, B). A consistent
improvement in ejection fraction measured by serial echo-
cardiography was observed in CorMatrix–ECM-treated an-
imals over the 16-week observation period (Figure 5, C).
Left ventricular end diastolic volumes approached normal
hearts in bFGF-enhanced CorMatrix-ECM animals and
but were significantly increased in both nonenhanced Cor-
Matrix–ECM-treated and sham animals (208.0  59.3 mL
vs 351.5  157.7 mL and 363.1  108.7 mL; P< .01)
(Figure 5, D). These data indicate left ventricle dilation in
sham and nonenhanced CorMatrix–ECM-treated animals
that was prevented in bFGF-enhanced CorMatrix–ECM-
treated animals. Cardiac output and stroke volume was
equivalent between normal, sham, nonenhanced, and
bFGF-enhanced CorMatrix–ECM-treated animals (cardiac
output: 46.2  16.7 mL/minute, 38.5  13.8 mL/minute,
35.2  10.5 mL/minute, and 37.8  10.4 mL/minute,
respectively; P ¼ .442; and stroke volume: 0.15  0.05
mL, 0.12  0.05 mL, 0.11  0.03 mL, and 0.12  0.03
mL, respectively; P ¼ .39) indicating that none of the ani-
mals, despite a substantial transmural infarct, developed
overt heart failure at 16 weeks.
The end-systolic pressure volume relationship, an index
of myocardial contractility, demonstrated preservation of
systolic function in both non-enhanced and bFGF-
enhanced CorMatrix–ECM-treated animals compared
with shams (0.709  0.306 and 0.609  0.160 vs 0.437 
0.218; P< .05) (Figure 5, E). The infarct area appeared
smaller and wall thickness increased in both nonenhanced
CorMatrix–ECM-treated and bFGF-enhanced CorMatrix–
ECM-treated animals compared with shams (Figure 1, A),
suggesting that improved contractility after epicardial
infarct repair may be the result of decreased infarct
expansion.
Left ventricular compliance was evaluated by left ven-
tricular end diastolic pressure measures, the end-diastolic
pressure volume relationship, and by passive pressure-
volume curves. Left ventricular end diastolic pressure was
equivalent in CorMatrix–ECM-treated (nonenhanced and
bFGF-enhanced) and sham animals (10.2  3.2 mm Hgpressure volume relationship (ESPVR) measured by PV loop 16 weeks
post-treatment. F, Ventricular compliancewas reflected by the end diastolic
pressure volume relationship (EDPVR) measured by PV loop 16 weeks
post-treatment. *P<.05. **P<.01. ***P<.001. ****P<.0001.
gery c May 2014
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addition, the end-diastolic pressure volume relationship was
also equivalent across study groups (0.10 0.04 and 0.08
0.04 vs 0.10  0.5; P ¼ .79) (Figure 5, F), indicating that
epicardial infarct repair does not alter left ventricle compli-
ance or restrict left ventricle filling. Passive pressure-
volume curves (Figure 1, C) showed similar chamber
compliance between untreated ECM and normal hearts
also indicating that epicardial CorMatrix-ECM therapy
does not restrict ventricular expansion.
DISCUSSION
ECM influences post-MI structural remodeling by
providing structural support to tissues. ECM also provides
a dynamic microenvironment that regulates cardiac cell
morphology, differentiation, migration, and proliferation.8
ECM homeostasis is maintained by resident cardiac fibro-
blasts.9 Ischemic insults trigger conversion of quiescent
fibroblasts to an active myofibroblast phenotype.10 Myofi-
broblasts alter ECM homeostasis by increasing ECM
turnover and stimulating scar formation to reinforce the
damaged region and prevent mechanical complications
such asmyocardial rupture.9 Remodeling of ECMearly after
MI is adaptive, but persistent ECM dysregulation results in
progressive myocardial fibrosis, ventricular dilation, and
heart failure.11,12 Matricellular proteins13 within the ECM
play a key role in regulating themicroenvironment of cardiac
fibroblasts7 and in so doing, serve as a potential therapeutic
target for novel interventions aimed at mitigating fibrosis.
We believe that targeting ECM dysregulation and restoring
key matricellular proteins after MI may improve myocardial
repair and prevent maladaptive structural remodeling.
Tissue engineering approaches aiming to mimic and
replace native tissue have utilized synthetic or decellularized
xenogenic ECM scaffolds with targeted ex vivo cell
repopulation.11,14-19 Acellular biologic scaffolds are
preferable over synthetic material as they promote host
cellular repopulation, tissue regeneration, growth, and
adaptive remodeling after implantation.20,21 We evaluated a
novel surgical approach that leverages a unique ECM
biomaterial (ie, CorMatrix-ECM) in combination with a
paracrine factor (ie, bFGF) capable of preventing maladap-
tive fibrosis and mobilizing endogenous regenerative cell
populations. We believe CorMatrix-ECM is an ideal plat-
form technology for epicardial infarct repair given its
biocompatibility, well-established safety profile, and imme-
diate commercial availability for use in cardiac surgery.
CorMatrix-ECM is a biologic porcine matrix scaffold
that retains its native 3-dimensional collagen architecture
and key matricellular proteins, including glycosaminogly-
cans, bFGF, fibronectin, and laminin.22-25 The potential of
this biomaterial has been clinically validated in several
noncardiac applications.20,21 Although the biomaterial is
xenogenic, in vivo studies have confirmed excellentThe Journal of Thoracic and Carhost immune tolerance.26,27 To date, it has been used safely
and effectively in numerous routine cardiac applications.28
In our study we demonstrate beneficial effects of
CorMatrix-ECM biomaterial patch on post-MI cardiac
remodeling. Epicardial application of CorMatrix-ECM
preserves native ECM architecture within an infarcted
myocardium and decreases regional scar formation.
Epicardial implantation of CorMatrix-ECM alters ECM
homeostasis toward reduced fibroblast activation and
fibrosis as suggested by the observed increase in bFGF
expression within the CorMatrix-ECM patch and host
myocardium. We demonstrate that enhancing CorMatrix-
ECM with bFGF before implantation can further improve
ECM homeostasis after infarction resulting in improved
chamber remodeling and cardiac function. Prevention of
left ventricle dilation likely resulted in the improved
ejection fraction observed with bFGF-enhanced epicardial
infarct repair. Regional infract scar was reduced in
CorMatrix–ECM-treated animals suggesting that epicardial
infarct repair prevents infarct expansion and preserves
contractile muscle. This proposed mechanism is supported
by the improved myocardial contractility observed in
CorMatrix–ECM-treated animals.
Our results illustrate a proof-of-concept for this novel
surgical procedure. Further validation of this novel therapy
in a preclinical large animal model is required. Clinical
safety concerns cannot be addressed in a translational
rodent study. However, we show that left ventricle
compliance was not altered by the procedure, thereby miti-
gating potential concerns about ventricular restriction from
the epicardial device implantation. These data are consis-
tent with the histologic analysis that shows an absence of
inflammation and scarring around the implant. Importantly,
these observations also confirm that the reduced chamber
volumes were not secondary to deleterious myocardial
restriction preventing physiologic chamber expansion.
Current surgical approaches for treatment of the ischemic
remodeled heart include surgical ventricular restoration or
epicardial-based ventricular restraint devices, designed to
reduce LV volumes and subsequently improve ejection frac-
tion. The clinical benefits of these strategies remain contro-
versial.29,30 Epicardial infarct repair offers a surgical
alternative that, unlike surgical ventricular restoration or
ventricular restraint devices, utilizes a biologically active
material capable of limiting the ischemic remodeling
process.
In this emerging era of tissue engineering and biosurgical
approaches to heart failure, we believe that passive girdling
with inert/synthetic patch materials should not be the pri-
mary goal of new therapies, recognizing that regional inert
epicardial infarct patches have shown short-term benefits in
animal models. To date, we have not seen effective clinical
translation of therapies using synthetic and inert materials
for epicardial restraint despite substantial efforts. Passivediovascular Surgery c Volume 147, Number 5 1657
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epicardial adhesions and scarring should be avoided. We
believe that synthetic inert patches have these complica-
tions and would not be capable of the responses observed
with CorMatrix ECM. Given that we noted a superior
response with bFGF enhancement compared with untreated
patches alone, these data suggest that the mechanism of
benefit with the enhanced biomaterial is due to active mo-
lecular and cellular responses as opposed to purely a passive
effect from adhesions and scarring given that both groups
had identical patches. Future studies could be performed
to better characterize the underlying mechanisms of benefit
in the attenuation of remodeling observed after epicardial
infarct repair with CorMatrix-ECM biomaterial patch. We
show that epicardial infarct repair restores ECM homeosta-
sis, preventing the underlying pathology that leads to ven-
tricular dilation following MI. We believe this platform
technology is clinically feasible and specifically targets
the active cellular and molecular changes that underlie
ischemic cardiomyopathy. Given our complete set of data,
there is no suggestion of chamber restriction due to scarring
or adhesion formation. This is an important distinction to
passive restraint due to chamber restriction from scarring.
Our data is consistent with the idea that an active process
of maladaptive chamber remodeling was attenuated over
time resulting in reduced chamber size. In a clinical setting,
epicardial infarct repair could be feasibly introduced as an
adjunct to surgical revascularization for patients with
regional ischemic myocardial injury at risk of progressive
maladaptive remodeling. In a recent multicenter trial, 5%
of patients admitted with an acute coronary syndrome
received coronary artery bypass grafting surgery during
the index hospitalization and over 10% of patients with
acute coronary syndrome had coronary bypass graft surgery
within 12 months of the event.31 More than 1.4 million pa-
tients are admitted to hospitals with acute coronary syn-
drome each year in the United States, supporting the idea
that a significant subset of patients has surgical revascular-
ization within the timeline employed by the design of our
study. These patients are at higher risk for incomplete revas-
cularization and the subacute infarct region is ignored at the
time of coronary artery bypass graft. We believe this is an
opportunity to treat the progressive and dynamic infarct re-
gion. Based on the functional and structural improvements
observed in this study, we believe that epicardial infarct
repair as an adjunct to coronary bypass grafting may be
capable of reversing ischemic remodeling, improving
long-term clinical outcomes compared with coronary artery
bypass or percutaneous coronary intervention alone. The
ideal candidates are patients with viable myocardial regions
early after injury that faces the risk of progressive post-MI
remodeling despite revascularization. Further preclinical
studies will help optimize the potential clinical scenarios
and patient populations to target with this innovation.1658 The Journal of Thoracic and Cardiovascular SurPrevious studies aimed at developing functional myocar-
dial constructs for use after ischemic injury have utilized
ex vivo scaffold-based stem cell repopulation tech-
niques.15,19,32 The clinical applicability of this approach is
limited by the sparse availability of autologous stem cells,
possible immunosuppressive medication protocols, and the
lack of an ‘‘off-the-shelf’’ approach. Implantation of a
commercially available biocompatible acellular scaffold
capable of being repopulated with endogenous cells in vivo
would eliminate these barriers to adoption. We demonstrate
that host cells are capable of a robust repopulation of the
acellular CorMatrix-ECM biomaterial when implanted
onto the epicardial surface of a post-MI heart. Previous
studies demonstrate that enhancement of biologic ECMscaf-
folds with matricellular proteins increase the efficiency of
scaffold-based cellular repopulation.33,34 Our data support
this conclusion, demonstrating an increase in bFGF-
expressing cells within the CorMatrix-ECM biomaterial
when enhanced with bFGF before implantation. These data
highlight the ability to achieve in vivo tissue regeneration
without the need for exogenous cell repopulation.
Although bFGF is known to decrease fibrosis, its clinical
administration has remained problematic. Epicardial infarct
repair offers a feasible approach for regional tissue-specific
delivery ofbFGFas anantifibroticmyocardial treatment strat-
egy. We believe epicardial infarct repair is a promising plat-
form technology that can be tailored to the individual
patient. We aim to explore material enhancement with addi-
tional matricellular proteins known to regulate tissue remod-
eling after injury, such as endogenous tissue inhibitors of
metalloproteinases to suppress ECM turnover35 and vascular
endothelial growth factor, to stimulate angiogenesis.36,37
There are a number of study limitations to consider. First,
animals were matched for infarct size using functional data
that were not confirmed by histologic analysis. Second, wall
thickness was not quantitatively assessed and compared be-
tween groups, only a qualitative assessment was provided.
Third, the rodent infarct model may not be reflective of
the human condition. These issues may be best addressed
with further validation in large preclinical animal models.CONCLUSIONS
Epicardial infarct repair favorably alters cardiac remod-
eling post-MI, mitigating ischemic heart failure. These
data establish proof-of-concept for this novel surgical pro-
cedure in a small animal model. Epicardial infarct repair
should be further validated in a preclinical model before
translation into human patients.References
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